Drug intelligence / Profile preview

NNC 0113-0987

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Peptides, Small Molecules
Administration: Oral, Injection

Overview

NNC 0113-0987 is an investigational oral drug developed by Novo Nordisk for the treatment of type 2 diabetes. It is a long-acting glucagon-like peptide‑1 (GLP‑1) receptor agonist designed to improve glycemic control by mimicking the action of endogenous GLP‑1. This mechanism enhances insulin secretion in response to elevated blood glucose and suppresses glucagon release. NNC 0113‑0987 was formulated for oral administration using absorption enhancers such as sodium caprate and has also been studied via injection. The drug aimed to address unmet needs in type 2 diabetes management where many patients do not achieve target glucose levels with existing therapies[1][3].

Other names: long-acting GLP-1 analogue - novo nordisknon-invasive GLP-1 - novo nordisk

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on NNC 0113-0987.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC 0113-0987.

Explore the full profile